IO Biotech IncNASDAQ:IOBT
- LAST PRICE1.4200
- TODAY'S CHANGE (%)-0.0300 (-2.0690%)
- Bid / Lots1.3700/ 1
- Ask / Lots1.5400/ 1
- Open / Previous Close1.4300 / 1.4500
- Day Range
- 52 Week Range
- Volume73,378
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IOBT |
|---|---|---|
| 09:32 ET | 557 | 1.43 |
| 09:36 ET | 3000 | 1.4478 |
| 09:57 ET | 5000 | 1.43 |
| 10:01 ET | 1000 | 1.42 |
| 10:19 ET | 112 | 1.44 |
| 10:21 ET | 100 | 1.44 |
| 10:51 ET | 200 | 1.45 |
| 11:02 ET | 300 | 1.53 |
| 11:04 ET | 200 | 1.45 |
| 11:13 ET | 200 | 1.5 |
| 11:33 ET | 4792 | 1.45 |
| 11:36 ET | 400 | 1.45 |
| 11:51 ET | 3133 | 1.44 |
| 11:58 ET | 1696 | 1.44 |
| 12:14 ET | 300 | 1.43 |
| 12:25 ET | 1279 | 1.44 |
| 12:32 ET | 100 | 1.43 |
| 12:38 ET | 1701 | 1.43 |
| 12:50 ET | 200 | 1.43 |
| 01:30 ET | 315 | 1.43 |
| 01:37 ET | 7520 | 1.43 |
| 01:53 ET | 1500 | 1.43 |
| 01:55 ET | 6160 | 1.42 |
| 02:08 ET | 1300 | 1.42 |
| 02:09 ET | 200 | 1.42 |
| 02:38 ET | 386 | 1.42 |
| 02:45 ET | 200 | 1.42 |
| 02:58 ET | 4018 | 1.43 |
| 03:27 ET | 16544 | 1.42 |
| 03:43 ET | 799 | 1.41 |
| 03:45 ET | 2239 | 1.425 |
| 03:56 ET | 748 | 1.43 |
| 03:57 ET | 1366 | 1.416 |
| 03:59 ET | 1200 | 1.42 |
Apr 24, 2024
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, from 4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
4:30PM ET on Wednesday Apr 24, 2024 by Dow Jones
Apr 15, 2024
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness, from 8:30AM ET on Monday Apr 15, 2024 by Dow Jones
8:30AM ET on Monday Apr 15, 2024 by Dow Jones
Apr 9, 2024
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103, from 12:00PM ET on Tuesday Apr 09, 2024 by Dow Jones
12:00PM ET on Tuesday Apr 09, 2024 by Dow Jones
Apr 5, 2024
IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer, from 8:30AM ET on Friday Apr 05, 2024 by Dow Jones
8:30AM ET on Friday Apr 05, 2024 by Dow JonesPress Release: IO Biotech Appoints Fai al Miyara, Ph.D., as Chief Business Officer, from 8:30AM ET on Friday Apr 05, 2024 by Dow Jones
8:30AM ET on Friday Apr 05, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
IO Biotech Inc | 95.5M | -0.7x | --- |
Eliem Therapeutics Inc | 95.1M | -3.0x | --- |
DiaMedica Therapeutics Inc | 96.0M | -4.2x | --- |
Vigil Neuroscience Inc | 97.0M | -1.3x | --- |
Anixa Biosciences Inc | 95.1M | -9.4x | --- |
Elicio Therapeutics Inc | 93.1M | -1.0x | --- |
Company Information
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Contact Information
- Headquarters
- Ole Maaloes Veh 3COPENHAGEN, Denmark 2200
- Phone
- ---
- Fax
- ---
Executives
- Chairman of the Board
- Peter Hirth
- President, Chief Executive Officer, Founder, Director
- Mai-Britt Zocca
- Chief Financial Officer
- Amy Sullivan
- Chief Accounting Officer
- Brian Burkavage
- Chief Scientific Officer
- Muhammad Al-hajj
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $95.5M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 65.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-2.15 |
Book Value | $2.02 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
